TEE
AMAG

Tibra Equities Europe’s AMAG Pharmaceuticals AMAG Stock Holding History

Tibra Equities Europe’s Portfolio AMAG Stock Details AMAG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-35,400
Closed -$456K – 506
2019
Q1 		$456K Buy
+35,400
New +$527K 0.05% 277

Other funds holding AMAG

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Tibra Equities Europe's AMAG Position: Q2 2019 in Review

Tibra Equities Europe sold out of AMAG Pharmaceuticals (AMAG) in Q2 2019, closing a stake of 35,400 shares — an estimated $456K sold.

Tibra Equities Europe first reported a position in AMAG in Q1 2019 and held it in 1 quarter. The position peaked at $456K in Q1 2019. 170 funds tracked by Wall St. Rank hold AMAG as of Q2 2019.

  • Tibra Equities Europe reported no remaining AMAG Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Tibra Equities Europe sold 35,400 AMAG Pharmaceuticals shares in Q2 2019, an estimated $456K.
  • Tibra Equities Europe first reported a position in AMAG Pharmaceuticals in Q1 2019 and held it in 1 quarter.
  • Tibra Equities Europe's AMAG Pharmaceuticals position peaked at $456K in Q1 2019.
  • 170 funds tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q2 2019.

Based on Tibra Equities Europe's 13F filing for Q2 2019, filed 1 Aug 2019.